European Commission Approves BioMarin's VOXZOGO® (vosor

European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

European Commission Approves BioMarin's VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close

prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Related Keywords

Germany , Italy , United States , France , Magdeburg , Sachsen Anhalt , French , America , German , Klaus Mohnike , Debra Charlesworth , Biomarin Voxzogo , Carmen Alonso Alvarez , Autorisation Temporaire , Asia Pacific , Traci Mccarty , Jean Jacques Bienaim , Health Products Safety , French National Agency For Medicines , European Commission , Drug Administration , Biomarin Pharmaceutical Inc , Nasdaq , Exchange Commission , Professor Of Paediatrics At Magdeburg University Hospital , Biomarin Pharmaceutical , Magdeburg University Hospital , Middle East , French National Agency , Temporary Authorization , Chief Executive Officer , Managing Director , Drug Application , Prescription Drug User Fee Act , Priority Review Designation , Priority Review Voucher , Orphan Drug Designation , Latin America , Action Date , Priority Review , Quarterly Report ,